In this issue
New real-world evidence for efgartigimod in chronic inflammatory demyelinating polyneuropathy (CIDP) presented at the AAN and PNS congresses in 2026 provides important insights to help neurologists navigate its use in daily clinical practice, tackling key practical questions such as selecting patients for treatment and successfully switching from current therapy.
Rate this content's potential impact on patient outcomes
Average rating / 5. Vote count:
No votes so far! Be the first to rate this content.
Latest articles
All articles


We’ve noticed you’re accessing
from North/South America.
from North/South America.